Autres langues BioNTech SE

Actions

BNTX

US09075V1026

Recherche biotechnologique et médicale

Temps réel estimé 20:15:48 21/09/2026 Varia. 5j. Varia. 1 janv.
98,35 USD +2,38% Graphique intraday de BioNTech SE -1,06% +2,74%

Autres langues

18:06 European Equities Traded in the US as American depositary Receipts Rise in Monday Trading
18/09 Biontech Insider Sold Shares Worth $6,239,071, According to a Recent SEC Filing
18/09 European Equities Traded in the US as American Depositary Receipts Drop in Friday Trading
17/09 Pfizer Canada ULC And BioNTech SE Receive Health Canada Authorization For Omicron XFG-Adapted COMIRNATY COVID-19 Vaccine
17/09 Pfizer, BioNTech Secure Health Canada Authorization for Omicron XFG-Adapted COVID-19 Vaccine
17/09 Health Canada Authorizes Pfizer and BioNTech's Omicron XFG-Adapted COVID-19 Vaccine
16/09 Biontech Insider Sold Shares Worth $4,721,976, According to a Recent SEC Filing
16/09 Berenberg hebt Ziel für Biontech auf 140 Dollar - 'Buy'
15/09 European Equities Traded in the US as American Depositary Receipts Decline in Tuesday Trading
14/09 BioNTech, OncoC4 Report Positive Overall Survival Data From Phase 3 Trial of Gotistobart in Lung Cancer
14/09 BioNTech, OncoC4's Gotistobart Boosts Survival in Non-small Cell Lung Cancer Study
14/09 BioNTech verzeichnet Etappenerfolg mit neuem Lungenkrebsmittel
14/09 BioNTech says lung cancer drug candidate prolonged lives in trial
14/09 BioNTech and OncoC4 Present Updated Data Showing Gotistobart Nearly Doubled Median Overall Survival versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
14/09 Neue Daten zu Gotistobart zeigten annähernde Verdopplung des medianen Gesamtüberlebens im Vergleich zur Standardchemotherapie bei Patientinnen und Patienten mit zuvor behandeltem Plattenepithelkarzinom der Lunge
14/09 BioNTech And OncoC4 Present Updated Data Showing Gotistobart Nearly Doubles Median Overall Survival Versus Standard-of-Care Chemotherapy in Previously Treated Squamous Non-Small Cell Lung Cancer Patients
11/09 Biontech Insider Sold Shares Worth $1,974,287, According to a Recent SEC Filing
10/09 European Equities Traded in the US as American Depositary Receipts Drop in Thursday Trading
08/09 Biontech Insider Sold Shares Worth $7,889,055, According to a Recent SEC Filing
08/09 European Equities Traded in the US as American Depositary Receipts Fall in Tuesday Trading
04/09 European Equities Traded in the US as American Depositary Receipts Marginally Higher in Friday Trading
01/09 GSK überführt mRNA-Grippeimpfstoff in die nächste Studienphase
01/09 GSK Moves mRNA Flu Vaccine Candidate to Late-Stage Trial
28/08 Health Care Down, But not by Much, on Rotation Out of Rate-Sensitive Areas - Health Care Roundup
28/08 BioNTech SE And Genentech Terminate Phase 2 Clinical Trial Collaboration For Autogene Cevumeran In Resected Colorectal Cancer
Aucun résultat pour cette recherche
-40% : Prolongation exceptionnelle ➤➤➤➤
j
:
:
PROFITEZ-EN MAINTENANT